Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
暂无分享,去创建一个
M. Konopleva | M. Andreeff | H. Kantarjian | J. Cortes | F. Ravandi | Q. Bashir | M. Qazilbash | R. Champlin | M. de Lima | S. Giralt | U. Bayraktar | P. Kebriaei | Julianne J Chen | Manish Sharma | Alexandre Chiattone | Deborah A McCue | Deborah McCue | Deborah Mccue
[1] N. Mounier,et al. New sequential treatment with chemotherapy and reduced‐intensity conditioning for allogeneic stem‐cell transplantation in very high‐risk acute myeloid leukemia , 2011, American journal of hematology.
[2] P. Thall,et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] P. Chiusolo,et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. , 2011, Leukemia research.
[4] M. Konopleva,et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias , 2011, Haematologica.
[5] Krishna Komanduri,et al. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.
[6] P. Thall,et al. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation , 2010 .
[7] E. Estey,et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] R. Childs,et al. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. , 2010, Blood.
[9] A. Mackensen,et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. , 2010, Leukemia research.
[10] A. Lebeau,et al. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation , 2010, Journal of Clinical Pathology.
[11] Kathleen M Murphy,et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. , 2010, Blood.
[12] M. Eilers,et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. , 2009, Blood.
[13] E. Estey,et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.
[14] I. Bruns,et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. , 2009, Leukemia research.
[15] M. Konopleva,et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. , 2008, Journal of the National Cancer Institute.
[16] H. Kantarjian,et al. Potential role of sorafenib in the treatment of acute myeloid leukemia , 2008, Leukemia & lymphoma.
[17] E. Shpall,et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation , 2007, Leukemia.
[18] W. Hofmann,et al. The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia , 2007 .
[19] W. Hofmann,et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. , 2007, Blood.
[20] P. Dent,et al. Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.
[21] G. Gores,et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.
[22] G. Ledderose,et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[25] B. Löwenberg,et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene , 2000, Leukemia.
[26] 早川 文彦. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000 .
[27] T. Naoe,et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.
[28] L. Kumar,et al. Leukemia: management of relapse after allogeneic bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Morel,et al. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation , 2022 .